Abstract
Daily treatment of systemic mastocytosis with high-dose interferon-alfa often is not tolerated because of clinical or hematologic side effects. We report successful treatment of a patient with systemic mastocytosis, who was positive for the D816V mutation, with interferon alfa-2b at 10 million units three times per week. During 5 years of treatment, bone marrow infiltration by mast cells decreased from 50 to ≤5%, and there was a decrease (urinary N-methylhistamine excretion, 75%; serum tryptase concentration, 98%) or normalization (serum calcitonin value, urinary prostaglandin F 2α excretion) of mast cell mediators. Side effects included mild depression (untreated) and biochemical hypothyroidism easily managed with supplemental levothyroxine.
Original language | English (US) |
---|---|
Pages (from-to) | 131-134 |
Number of pages | 4 |
Journal | Leukemia Research |
Volume | 29 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2005 |
Keywords
- Interferon-alfa
- Prostaglandin F
- Systemic mastocytosis therapy
- Tryptase
- c-kit mutation
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research